Epidermolysis bullosa

5 trials 5 recruiting MedDRA PT
5 Registered trials
5 Recruiting
4 Unique sponsors
20 Unique IMPs
2 Commercial trials
Drug classes (ATC)
ATC code not specified 3
H Endocrinology (ATC H) 1
N Neurology/Psychiatry (ATC N) 1
R Respiratory (ATC R) 1
C Cardiology (ATC C) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 16 substances
Corticosteroid 3 substances
JAK inhibitor 1 substance
Phase III: 1 Phase II: 3 Phase I (First in Human): 1

Filter these 5 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 5 trials

Phase III

1 trial
  • Rheacell GmbH & Co. KG Commercial
    ALLOGENEIC SKIN-DERIVED ABCB5-POSITIVE DERMAL MESENCHYMAL STROMAL CELLS; CETIRIZINE DIHYDROCHLORIDE; CHLOROPYRAMINE HYDROCHLORIDE; CHLORPHENAMINE MALEATE; CLEMASTINE FUMARATE; DESLORATADINE; DEXCHLORPHENIRAMINE MALEATE; DIPHENHYDRAMINE HYDROCHLORIDE; FEXOFENADINE HYDROCHLORIDE; HYDROCORTISONE SODIUM PHOSPHATE; LEVOCETIRIZINE DIHYDROCHLORIDE; LORATADINE; METHYLPREDNISOLONE; PREDNISOLONE SODIUM SUCCINATE; PROMETHAZINE HYDROCHLORIDE; RUPATADINE
    2022-500266-10-00 12 countries 2023 n=119 Orphan
    Recruiting

Phase II

3 trials
  • Xinnate AB Commercial
    H-GLY-LYS-TYR-GLY-PHE-TYR-THR-HIS-VAL-PHE-ARG-LEU-LYS-LYS-TRP-ILE-GLN-LYS-VAL-ILE-ASP-GLN-PHE-GLY-GLU-OH
    2024-515172-12-00 5 countries 2025 n=26
    Recruiting
  • Centre Hospitalier Universitaire De Nantes Academic
    DEUCRAVACITINIB
    2022-502879-32-00 1 country 2024 n=10
    Recruiting
  • Centre Hospitalier Universitaire De Nantes Academic
    COLESTYRAMINE
    2023-505116-37-00 1 country 2024 n=40
    Recruiting

Phase I (First in Human)

1 trial
  • Institut National De La Sante Et De La Recherche Medicale Academic
    AUTOLOGOUS KERATINOCYTES AND FIBROBLASTS TRANSDUCED WITH A RETROVIRAL VECTOR ENCODING COL7A1 CDNA
    2024-518368-10-00 1 country 2025 n=3
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Centre Hospitalier Universitaire De Nantes Academic 2 Phase II 2
Xinnate AB Commercial 1 Phase II 1
Rheacell GmbH & Co. KG Commercial 1 Phase III 1
Institut National De La Sante Et De La Recherche Medicale Academic 1 Phase I (First in Human) 1
New trials by year
2023
1
2024
2
2025
2
← All indication landscapes